Please note that slides are for review only and not to be repurposed or published.

Consensus or Controversy? Targeted Treatment Of Non-Small Cell Lung Cancer | Part 1 of a 2-Part Series

MODULE 1:
Optimal Testing Algorithms; Treatment of Patients with EGFR Tumor Mutations

MODULE 2:
Treatment of Patients with ALK and ROS1 Tumor Alterations

MODULE 3:
Treatment of Patients with Other Potentially Targetable Tumor Mutations (BRAF V600E, MET, RET, et cetera)

Consensus or Controversy? Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Without Targetable Tumor Mutations | Part 2 of a 2-Part Series

MODULE 1:
Front-Line Treatment

MODULE 2:
Second- and Later-Line Therapy

MODULE 3:
Toxicities Associated with and Relative Contraindications to Immune Checkpoint Inhibition

MODULE 4:
Ongoing Investigation, Future Directions with Immune Checkpoint Inhibitors